Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H22O3 |
Molecular Weight | 310.3869 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C
InChI
InChIKey=XNEFYCZVKIDDMS-UHFFFAOYSA-N
InChI=1S/C20H22O3/c1-20(2,3)16-9-5-14(6-10-16)18(21)13-19(22)15-7-11-17(23-4)12-8-15/h5-12H,13H2,1-4H3
Molecular Formula | C20H22O3 |
Molecular Weight | 310.3869 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/Avobenzone | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3fd7fb-4a28-4db8-9a4d-d7fdd2e45daf
Curator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/Avobenzone | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3fd7fb-4a28-4db8-9a4d-d7fdd2e45daf
Avobenzone is an oil soluble ingredient used in sunscreen products to absorb the full spectrum of UVA rays. It helps prevent sunburn. Avobenzone works by absorbing the rays and converting them to energy that is less damaging to the skin.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31058986/ |
832.5 mg 4 times / day multiple, topical dose: 832.5 mg route of administration: Topical experiment type: MULTIPLE co-administered: OCTOCRYLENE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31058986/ |
810 mg 4 times / day multiple, topical dose: 810 mg route of administration: Topical experiment type: MULTIPLE co-administered: OXYBENZONE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.4 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
810 mg 4 times / day multiple, topical dose: 810 mg route of administration: Topical experiment type: MULTIPLE co-administered: OXYBENZONE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.8 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
576 mg 4 times / day multiple, topical dose: 576 mg route of administration: Topical experiment type: MULTIPLE co-administered: OCTOCRYLENE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
591.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31058986/ |
832.5 mg 4 times / day multiple, topical dose: 832.5 mg route of administration: Topical experiment type: MULTIPLE co-administered: OCTOCRYLENE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
350.1 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31058986/ |
810 mg 4 times / day multiple, topical dose: 810 mg route of administration: Topical experiment type: MULTIPLE co-administered: OXYBENZONE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
112.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31058986/ |
832.5 mg 4 times / day multiple, topical dose: 832.5 mg route of administration: Topical experiment type: MULTIPLE co-administered: OCTOCRYLENE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
94.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31058986/ |
810 mg 4 times / day multiple, topical dose: 810 mg route of administration: Topical experiment type: MULTIPLE co-administered: OXYBENZONE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
45.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
810 mg 4 times / day multiple, topical dose: 810 mg route of administration: Topical experiment type: MULTIPLE co-administered: OXYBENZONE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
33 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
576 mg 4 times / day multiple, topical dose: 576 mg route of administration: Topical experiment type: MULTIPLE co-administered: OCTOCRYLENE |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.7 g 1.3 times / day multiple, topical Recommended Dose: 3.7 g, 1.3 times / day Route: topical Route: multiple Dose: 3.7 g, 1.3 times / day Sources: |
healthy, 3.69 years (range: 0.64-48.15 years) Health Status: healthy Age Group: 3.69 years (range: 0.64-48.15 years) Sex: M+F Sources: |
Other AEs: Dermatitis, Eczema... |
1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Other AEs: Acne, Dermatitis... Other AEs: Acne (4.8%) Sources: Dermatitis (2.8%) Dry skin (1.2%) Eczema (1.2%) Erythema (1.2%) Pruritus (2%) Rosacea (0.4%) Seborrhea (0.8%) Skin discomfort (1.2%) Sunburn (0.8%) Conjunctivitis (0.8%) Taste perversion (0.4%) |
3.1 g 1.2 times / day multiple, topical Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Sources: |
healthy, 6.69 years (range: 0.5-67.95 years) Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Sources: |
Other AEs: Dermatitis, Eczema... Other AEs: Dermatitis (2.8%) Sources: Eczema (0.4%) Erythema (0.8%) Skin discomfort (0.8%) Sunburn (1.6%) Conjunctivitis (0.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Eczema | 1.3% | 3.7 g 1.3 times / day multiple, topical Recommended Dose: 3.7 g, 1.3 times / day Route: topical Route: multiple Dose: 3.7 g, 1.3 times / day Sources: |
healthy, 3.69 years (range: 0.64-48.15 years) Health Status: healthy Age Group: 3.69 years (range: 0.64-48.15 years) Sex: M+F Sources: |
Dermatitis | 2.5% | 3.7 g 1.3 times / day multiple, topical Recommended Dose: 3.7 g, 1.3 times / day Route: topical Route: multiple Dose: 3.7 g, 1.3 times / day Sources: |
healthy, 3.69 years (range: 0.64-48.15 years) Health Status: healthy Age Group: 3.69 years (range: 0.64-48.15 years) Sex: M+F Sources: |
Rosacea | 0.4% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Taste perversion | 0.4% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Conjunctivitis | 0.8% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Seborrhea | 0.8% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Sunburn | 0.8% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Dry skin | 1.2% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Eczema | 1.2% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Erythema | 1.2% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Skin discomfort | 1.2% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Pruritus | 2% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Dermatitis | 2.8% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Acne | 4.8% | 1.6 g 1.1 times / day multiple, topical Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Sources: |
healthy, 35.44 years (range: 12.04-83.43 years) Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Sources: |
Conjunctivitis | 0.4% | 3.1 g 1.2 times / day multiple, topical Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Sources: |
healthy, 6.69 years (range: 0.5-67.95 years) Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Sources: |
Eczema | 0.4% | 3.1 g 1.2 times / day multiple, topical Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Sources: |
healthy, 6.69 years (range: 0.5-67.95 years) Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Sources: |
Erythema | 0.8% | 3.1 g 1.2 times / day multiple, topical Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Sources: |
healthy, 6.69 years (range: 0.5-67.95 years) Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Sources: |
Skin discomfort | 0.8% | 3.1 g 1.2 times / day multiple, topical Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Sources: |
healthy, 6.69 years (range: 0.5-67.95 years) Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Sources: |
Sunburn | 1.6% | 3.1 g 1.2 times / day multiple, topical Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Sources: |
healthy, 6.69 years (range: 0.5-67.95 years) Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Sources: |
Dermatitis | 2.8% | 3.1 g 1.2 times / day multiple, topical Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Sources: |
healthy, 6.69 years (range: 0.5-67.95 years) Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Multiple chemical sensitivities, including iatrogenic allergic contact dermatitis, in a patient with chronic actinic dermatitis: implications for management. | 1996 Sep |
|
Photochemical studies of 4-tert-butyl-4'-methoxydibenzoylmethane (BM-DBM). | 2001 Nov 15 |
|
Photostabilization of butyl methoxydibenzoylmethane (Avobenzone) and ethylhexyl methoxycinnamate by bis-ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S), a new UV broadband filter. | 2001 Sep |
|
The effect of UV absorbing sunscreens on the reflectance and the consequent protection of skin. | 2002 Feb |
|
A new model using liposomes that allow to distinguish between absorption and oxidative properties of sunscreens. | 2002 Jan |
|
The effects of derivatives of the nitroxide tempol on UVA-mediated in vitro lipid and protein oxidation. | 2002 Jul 1 |
|
Protection against UVB irradiation by natural filters extracted from lichens. | 2002 Nov |
|
Non-invasive in vivo determination of UVA efficacy of sunscreens using diffuse reflectance spectroscopy. | 2003 Aug |
|
Bioconvertible vitamin antioxidants improve sunscreen photoprotection against UV-induced reactive oxygen species. | 2003 Nov-Dec |
|
Lack of in vitro protection by a common sunscreen ingredient on UVA-induced cytotoxicity in keratinocytes. | 2004 Oct 15 |
|
Determination of sixteen UV filters in suncare formulations by high-performance liquid chromatography. | 2004 Sep 17 |
|
Photochemical behavior of a new long-chain UV absorber derived from 4-tert-butyl-4'-methoxydibenzoylmethane. | 2004 Sep-Oct |
|
Interaction of polycyclic musks and UV filters with the estrogen receptor (ER), androgen receptor (AR), and progesterone receptor (PR) in reporter gene bioassays. | 2005 Feb |
|
Sunscreen penetration of human skin and related keratinocyte toxicity after topical application. | 2005 Jul-Aug |
|
A new long-chain UV absorber derived from 4-tert-butyl-4'-methoxydibenzoylmethane: absorbance stability under solar irradiation. | 2005 Mar-Apr |
|
Unexpected photolysis of the sunscreen octinoxate in the presence of the sunscreen avobenzone. | 2005 Mar-Apr |
|
Sun protection strength of a hydroquinone 4%/retinol 0.3% preparation containing sunscreens. | 2006 Apr |
|
Evaluation of the photostability of different UV filter combinations in a sunscreen. | 2006 Jan 13 |
|
Changes in ultraviolet absorbance and hence in protective efficacy against lipid peroxidation of organic sunscreens after UVA irradiation. | 2006 Mar 1 |
|
Design of a photostabilizer having built-in antioxidant functionality and its utility in obtaining broad-spectrum sunscreen formulations. | 2006 May-Jun |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Interactions between different solar UVB/UVA filters contained in commercial suncreams and consequent loss of UV protection. | 2006 Sep |
|
The FDA approves new over-the-counter sunscreen. | 2006 Sep-Oct |
|
[Simultaneous determination of 9 ultraviolet absorbers in cosmetics by high-performance liquid chromatography]. | 2007 |
|
I've heard there's a new sunscreen that's supposed to offer better skin protection. Can you tell me more? | 2007 Jun |
|
A new sunscreen agent. | 2007 May 21 |
|
Transient enol isomers of dibenzoylmethane and avobenzone as efficient hydrogen donors toward a nitroxide pre-fluorescent probe. | 2007 May-Jun |
|
Degradation kinetics of butylmethoxydibenzoylmethane (avobenzone) in aqueous solution. | 2007 Oct |
|
Photostability and efficacy studies of topical formulations containing UV-filters combination and vitamins A, C and E. | 2007 Oct 1 |
|
Mexoryl: a review of an ultraviolet a filter. | 2007 Sep 15 |
|
OTC product: Anthelios SX. | 2007 Sep-Oct |
|
In vitro assessments of UVA protection by popular sunscreens available in the United States. | 2008 Dec |
|
Influence of hydroxypropyl-beta-cyclodextrin on transdermal penetration and photostability of avobenzone. | 2008 Jun |
|
Assessing retinol stability in a hydroquinone 4%/retinol 0.3% cream in the presence of antioxidants and sunscreen under simulated-use conditions: a pilot study. | 2008 Mar |
|
Evaluation of spray congealing as technique for the preparation of highly loaded solid lipid microparticles containing the sunscreen agent, avobenzone. | 2009 Aug |
|
Optical and electron paramagnetic resonance studies of the excited states of 4-tert-butyl-4'-methoxydibenzoylmethane and 4-tert-butyl-4'-methoxydibenzoylpropane. | 2009 Dec 3 |
|
A blocked diketo form of avobenzone: photostability, photosensitizing properties and triplet quenching by a triazine-derived UVB-filter. | 2009 Jan-Feb |
|
Addressing technical challenges associated with the FDA's proposed rules for the UVA in vitro testing procedure. | 2009 Nov-Dec |
|
Filter-filter interactions. Photostabilization, triplet quenching and reactivity with singlet oxygen. | 2010 Apr |
|
Characterization of the UVA protection provided by avobenzone, zinc oxide, and titanium dioxide in broad-spectrum sunscreen products. | 2010 Dec 1 |
|
Polymorphism and reversible mechanochromic luminescence for solid-state difluoroboron avobenzone. | 2010 Feb 24 |
|
True photoallergy to sunscreens is rare despite popular belief. | 2010 Jul-Aug |
|
A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescription 0.02% tretinoin product regimen. | 2010 Mar |
|
An Assessment of the Efficacy and Safety of CROSS Technique with 100% TCA in the Management of Ice Pick Acne Scars. | 2010 May |
|
Determination of organic UV filters in water by stir bar sorptive extraction and direct analysis in real-time mass spectrometry. | 2010 May |
|
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1. | 2013 Sep 5 |
|
Chemical allergens stimulate human epidermal keratinocytes to produce lymphangiogenic vascular endothelial growth factor. | 2015 Mar 1 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:56:01 GMT 2025
by
admin
on
Mon Mar 31 17:56:01 GMT 2025
|
Record UNII |
G63QQF2NOX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
142401
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
||
|
NCI_THESAURUS |
C851
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
||
|
CFR |
21 CFR 352.10
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05617MIG
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
45045
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | RxNorm | ||
|
AA-89
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
AVOBENZONE
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
6480
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
G63QQF2NOX
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
51040
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200522
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
DTXSID9044829
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
7423
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
G63QQF2NOX
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
274-581-6
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
m2151
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | Merck Index | ||
|
1045337
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
C47406
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
758680
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
4242
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
70356-09-1
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
DB09495
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY | |||
|
100000086882
Created by
admin on Mon Mar 31 17:56:01 GMT 2025 , Edited by admin on Mon Mar 31 17:56:01 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |